Skip directly to content



Hear more about disclosing details around our work with HCPs and HCOs from our UK Medical Director, Dr Berkeley Phillips.

We know that transparency is essential to building and maintaining confidence in us and in our medicines.

We want people to know, and understand, what we do and how we do it. We are committed to becoming more transparent about how we operate as a business and about the relationships we have with other organisations and individuals. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the value these relationships bring.

Our business is regulated by the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the pharmaceutical industry which has detailed provisions to ensure that pharmaceutical companies operate in a responsible, ethical and professional manner. The Code includes requirements for how we may work with healthcare professionals, healthcare organisations and patient advocacy groups and in recent years it has set down new requirements for greater transparency in these areas.

We strongly support the work the European Federation of Pharmaceutical Industries and Associations (EFPIA) and ABPI have done to improve transparency across the pharmaceutical industry.

Working with healthcare professionals, healthcare organisations and patient groups

Working with healthcare professionals (HCPs), healthcare organisations (HCOs) and patient groups allows us to share knowledge and in turn, helps us to better prevent, treat and cure disease and improve the quality of people’s lives.

Having working relationships beyond Pfizer means we can use our knowledge to help doctors get the best out of our medicines, allow our scientists to monitor the impact of our current treatments and plan our future ones and to work in partnership with the NHS to deliver more effective and efficient care.

Financial support for healthcare professionals

We think HCPs should be appropriately paid for the time they invest and expertise they offer, but it is right to continually review how this works in practice. Pfizer makes different types of payments to HCPs. On our payments reports page, you can explore our data on what we have paid HCPs for:

  • sharing their expertise with us as we design and develop medicines and help other doctors to get the most out of our treatments ("fees for service and consultancy");
  • any expenses we have reimbursed linked to consultancy work with us;
  • any financial support we have given for HCPs to further medical education and knowledge and keep abreast of new medical developments by attending medical meetings ("registration fees" or "travel and accommodation" support)

For further information on what these activities are, please visit our FAQ page.

Financial or other support for healthcare organisations

Pfizer has close working relationships with Healthcare Organisations as well as individuals and there are occasions when we may offer financial or other types of support to the NHS and other organisations. We have detailed information on our website, about:

  • donations and grants to HCOs (where Pfizer does not derive a benefit);
  • corporate sponsorship projects (where Pfizer can derive a benefit through the project);
  • where we have contributed to the cost of running an event or for someone to attend an event (“registration fees”);
  • any fees we have paid in return for a service they have provided; and any contribution we have given for travel and accommodation to medical meetings.

Financial or other support for patient groups

Pfizer exists to discover and develop medicines that save and improve lives in areas where patients have an unmet need. We can't succeed unless we have a true understanding of what patients need and where they feel we can best offer support.

To do this, we work with specialists who have expertise in a whole range of areas, including patient organisations. At times, we provide financial and other support. This includes:

  • charitable donations or sponsorships to support the groups' work;
  • paying for time and expert advice ("fees for service");
  • providing non-financial benefits or 'benefits in kind' when we partner or collaborate on projects.

All the details are provided here on our website.

Charitable giving and social investment

We also disclose all our charitable giving and social investments in the UK each year. We are proud to be in a position to make a positive impact through a range of social investment programmes which aim to support medicines development beyond industry, in academia and other healthcare organisations and to improve the health and wellbeing of communities close to our four UK sites and more widely across the UK.

Research and development

The pharmaceutical industry is the source of 9 in 10 medicines available today.1 While we develop and discover medicines in our own laboratories, we also work with third parties from across life sciences. Initiated in 2016, pharmaceutical companies now share data on how much they have spent on conducting research and development activities in the UK. The figures provided reflect what we have spent on partnership payments relating to running our own clinical trials and non-interventional studies, supporting others to run their own research in related areas ("investigator initiated research") and costs associated with supporting data monitoring committees. Read more about what we have spent last year.

You can find information about our clinical trials at Every trial we run involving our compounds is registered and made public. We publish information about the purpose of each trial, the eligibility of patients to join the trial and the location of the study. Find out more about how Pfizer runs and shares trial information.

  1. ABPI. The Medicine Development Process. Available at: [accessed June 2016]

PP-PFE-GBR-0143/Date of preparation June 2016